2015 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
12/30/15NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinson’s Disease
First Clinical Efficacy Study Investigating ND0612H Subcutaneously Delivered Liquid Levodopa/Carbidopa for the Treatment of Advanced Parkinson's Disease REHOVOT, Israel, Dec. 30, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the start of patient enrollment in a first efficacy trial of ND0612H, the company’s continuously administered subcutaneous levodopa/carbidopa solu... 
Printer Friendly Version
12/18/15NeuroDerm Added to the Nasdaq Biotechnology Index
REHOVOT, Israel, Dec. 18, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the company has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI), effective December 21, 2015. The Index is designed to track the performance of a set of Nasdaq-listed securities that are classified as biotechnology or pharmaceutical according to the Industry Classifi... 
Printer Friendly Version
11/12/15NeuroDerm CEO to Present at Upcoming Investor Conferences
REHOVOT, Israel, Nov. 12, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences: Jefferies Autumn 2015 Global Healthcare Conference taking place in London, from November 18 – 19, 2015. Dr. Lieberman's presentation will take place on Wednesday, November 18, at 3:20pm GMT, 10:20am ET. Op... 
Printer Friendly Version
11/11/15NeuroDerm Announces Third Quarter 2015 Financial Results
Company to Host Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third quarter ended September 30, 2015. "We made solid progress in the third quarter developing our next-generation treatments for Parkinson's disease through subcutaneous administration of the first ever l... 
Printer Friendly Version
11/11/15NeuroDerm Announces Streamlined U.S. Development Plan Following FDA Feedback on ND0612H and ND0612L for the Treatment of Parkinson's Disease
Based on FDA input, NeuroDerm is not required to conduct its largest Phase III pivotal trial of 360 patients Company to host conference call today at 8:30 a.m. ET REHOVOT, Israel, Nov. 11, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has modified its U.S. development plan for ND0612H and ND0612L, the company's continuous, subcutaneously delivered levodopa/... 
Printer Friendly Version
11/04/15NeuroDerm to Host Third Quarter 2015 Financial Results Conference Call on November 11, 2015
REHOVOT, Israel, Nov. 4, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the third quarter of 2015 before the market opens on Wednesday, November 11, 2015. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. To access the call, dial 888-389-5988 (U.S.... 
Printer Friendly Version
09/24/15NeuroDerm Announces 2015 Annual General Meeting of Shareholders
REHOVOT, Isreal, Sept. 24, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold its 2015 Annual General Meeting of Shareholders (the "Meeting") on Thursday, October 29, 2015 for the purposes of (i) re-electing its Class I director, Uwe Wascher, for a three-year term, (ii) ratifying the re-appointment of Kesselman & Kesselman, a member firm of Pricewaterhouse... 
Printer Friendly Version
08/06/15NeuroDerm Announces Second Quarter 2015 Financial Results and Provides Corporate Update
Company to Host Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel, Aug. 6, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ended June 30, 2015 and provided a corporate update. "We recently closed a successful public offering that increased the Company's cash position significantly, allowing us the necessary funds ... 
Printer Friendly Version
07/30/15NeuroDerm to Host Second Quarter 2015 Financial Results Conference Call on August 6, 2015
REHOVOT, Israel, July 30, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the second quarter of 2015 before the market opens on Thursday, August 6, 2015. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. To access the call, dial 888-572-7025 (U.S.) ... 
Printer Friendly Version
07/21/15NeuroDerm Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
REHOVOT, Israel, July 21, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the closing of its public offering of 4,524,698 ordinary shares at a price to the public of $17.00 per share, which includes 590,178 shares purchased pursuant to the full exercise of the underwriters' option to purchase additional shares. The gross proceeds to NeuroDerm were approximately $77 million. ... 
Printer Friendly Version
07/15/15NeuroDerm Ltd. Announces Pricing of Public Offering
REHOVOT, Israel, July 15, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the pricing of its public offering of 3,934,520 shares of its ordinary shares at a price to the public of $17.00 per share, before underwriting discounts. All of the ordinary shares are being offered by NeuroDerm. In addition, NeuroDerm has granted the underwriters a 30-day option to purchase up to an ... 
Printer Friendly Version
07/02/15NeuroDerm Ltd. Files Registration Statement for Proposed Follow-On Offering
REHOVOT, Israel, July 2, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed public offering of its ordinary shares. All of the shares will be offered by the Company. Jefferies LLC and Cowen and Company, LLC will act as joint book runners for the proposed of... 
Printer Friendly Version
06/18/15NeuroDerm Poster Selected for Blue Ribbon Highlights Session During 19th International Congress of Parkinson's Disease and Movement Disorders Annual Meeting
Clinical Data Presented Suggests That Stable Levodopa Plasma Levels Achieved in Parkinson's Disease (PD) Patients Following ND0612H Administration May Replace Surgery REHOVOT, Israel, June 18, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that its poster presentation, "Stable levodopa plasma levels with ND0612 (LD/CD for subcutaneous infusion) in Parkinson's disease (PD) patien... 
Printer Friendly Version
06/11/15NeuroDerm Announces Start of a Pharmacokinetic, Head-To-Head Comparison Study of ND0612H and Duodopa(R)
Study Will Determine Dosing and Bioavailability of the First, Subcutaneously Delivered Liquid Levodopa for the Treatment of Parkinson's Disease vs. Intra-Duodenal Levodopa Gel Infusion Requiring Surgical Intervention REHOVOT, Israel, June 11, 2015 (GLOBE NEWSWIRE) -- NeuroDerm, Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it has started a pharmacokinetic (PK) clinical study to determine the dosing o... 
Printer Friendly Version
06/09/15NeuroDerm's Latest Clinical Data Accepted as Late Breaking News to the International Parkinson and Movement Disorder Society's 19th International Congress on June 14-18, 2015 in San Diego
REHOVOT, Israel, June 9, 2015 (GLOBE NEWSWIRE) -- NeuroDerm (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced the company will present its latest data of its lead products, ND0612L and ND0612H, at the International Parkinson and Movement Disorder Society's 19th International Congress of Parkinson's Disease and Movement Disorders meeting taking place on June 14 to 18, 2015 in San Diego, CA. ND0612L and ND0612H are Neur... 
Printer Friendly Version
06/02/15NeuroDerm to Ring The Nasdaq Stock Market Opening Bell on June 3, 2015
REHOVOT, Israel, June 2, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that Oded S. Lieberman, PhD, CEO of NeuroDerm, will ring The Nasdaq Stock Market Opening Bell in New York on Wednesday, June 3, 2015. A live stream of the ceremony will be available at http://livestream.com/nasdaq/live from approximately 9:15 a.m. ET until 9:30 a.m. ET. Mr. Lieberman commented, ... 
Printer Friendly Version
05/27/15NeuroDerm Announces First Quarter 2015 Financial Results and Provides Corporate Update
Company to Host Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the first quarter ended March 31, 2015 and provided a corporate update. "We look forward to the start of our next clinical trial, a head-to-head pilot pharmacokinetic study comparing ND0612H, our subcutaneously ... 
Printer Friendly Version
05/26/15NeuroDerm CEO to Present at Jefferies 2015 Healthcare Conference on June 1, 2015
REHOVOT, Israel, May 26, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the Jefferies 2015 Healthcare Conference on June 1, 2015 at 3:30pm ET in New York. Dr. Lieberman will give a corporate overview and discuss the company's next-generation treatments for central nervous system disorders, including the company's flagship prod... 
Printer Friendly Version
05/20/15NeuroDerm to Host First Quarter 2015 Financial Results Conference Call on May 27, 2015
REHOVOT, Israel, May 20, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the first quarter of 2015 before the market opens on Wednesday, May 27, 2015. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. To access the call, dial 888-401-4669 (U.S.) or ... 
Printer Friendly Version
05/08/15NeuroDerm Announces Lifting of FDA Clinical Hold on ND0612, a Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease
ND0612H and ND0612L U.S. Clinical Development Cleared to Proceed REHOVOT, Israel, May 8, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on U.S. clinical studies of ND0612H and ND0612L, the company's primary product candidates, that are based on proprietary, subcutaneously-delivered Levodopa/Carbi... 
Printer Friendly Version
04/29/15NeuroDerm Files Annual Report on Form 20-F for the Year Ended December 31, 2014
REHOVOT, Israel, April 29, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2014 with the U.S. Securities and Exchange Commission ("SEC"). The annual report on Form 20-F, which contains its audited financial statements, can be accessed on the SEC's website at http://www.sec.gov as well as ... 
Printer Friendly Version
04/02/15NeuroDerm Announces Fourth Quarter and 2014 Fiscal Year Financial Results and Provides a Corporate Update
REHOVOT, Israel, April 2, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014. "We made significant progress in the past year advancing our portfolio of next-generation treatments for Parkinson's disease. In the fourth quarter, we were pleased to announce the positive results of our Phase II tri... 
Printer Friendly Version
04/01/15NeuroDerm to Announce Updated Topline Results of Phase II Study of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease at the 67th Annual Meeting of the American Academy of Neurology
REHOVOT, Israel, April 1, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that updated results from the Phase II Study assessing the safety, tolerability and pharmacokinetics (PK) of ND0612L will be presented at the American Academy of Neurology (AAN) 67th Annual Meeting taking place April 18 to 25, 2015 in Washington, DC. ND0612L is the low-dose product candidate of NeuroDerm... 
Printer Friendly Version
02/24/15NeuroDerm CEO to Present at Upcoming Investor Conferences
REHOVOT, Israel, Feb. 24, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences in March: Cowen and Company 35th Annual Health Care Conference taking place in Boston, Massachusetts from March 2 – 4, 2015. Dr. Lieberman's presentation will take place on Monday, March 2, at 2:50pm ET. 27... 
Printer Friendly Version
01/19/15NeuroDerm Announces Extraordinary General Meeting of Shareholders for Ratification of Election of External Directors and Adoption of Compensation Policy
REHOVOT, Israel, Jan. 19, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold an Extraordinary General Meeting of Shareholders on Monday, February 23, 2015 for the purposes of ratifying the election of the Company's external directors, Alla Felder and Jonathan Kalman, and adopting a compensation policy for the Company's executives and directors. The record date... 
Printer Friendly Version